LNTH - Lantheus Holdings Inc Stock Price, Fair Value and News

$59.77+1.22 (+2.08%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

LNTH Price Action

Last 7 days

1.7%

Last 30 days

5.2%

Last 90 days

11.1%

Trailing 12 Months

-32.5%

LNTH RSI Chart

LNTH Valuation

Market Cap

4.0B

Price/Earnings (Trailing)

23.64

Price/Sales (Trailing)

2.6

EV/EBITDA

13.5

Price/Free Cashflow

8.66

LNTH Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

LNTH Fundamentals

LNTH Revenue

Revenue (TTM)

1.5B

Rev. Growth (Yr)

1.39%

Rev. Growth (Qtr)

1.58%

LNTH Earnings

Earnings (TTM)

167.7M

Earnings Growth (Yr)

-78.82%

Earnings Growth (Qtr)

-64.74%

LNTH Profitability

EBT Margin

15.90%

Return on Equity

14.98%

Return on Assets

7.37%

Free Cashflow Yield

11.55%

LNTH Investor Care

Buy Backs (1Y)

4.62%

Diluted EPS (TTM)

2.37

LNTH Alerts

Big fall in earnings (Y/Y)

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	1.5B	1.5B	1.5B	0
2024	1.4B	1.4B	1.5B	1.5B
2023	1.0B	1.1B	1.2B	1.3B
2022	541.6M	664.2M	801.5M	935.1M
2021	341.2M	376.3M	389.8M	425.2M
2020	351.5M	331.8M	334.6M	339.4M
2019	347.3M	347.4M	344.3M	347.3M
2018	332.6M	329.4M	338.3M	343.4M
2017	306.7M	317.6M	324.5M	331.4M
2016	295.1M	299.8M	298.7M	301.9M
2015	303.1M	300.8M	299.2M	293.5M
2014	0	289.6M	295.6M	301.6M
2013	0	0	0	283.7M

Get all data in R, Python etc through our Historical Stock Data APIs

About Lantheus Holdings Inc

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable Tc-99m-labeled imaging agent. The company also offers AZEDRA, a radiotherapeutic therapy; Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; PNT2002 for pre-chemotherapy patients; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; and PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer. The company serves hospitals, independent diagnostic testing facilities, government facilities, integrated delivery networks, radiopharmacies, clinics, distirbutors, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; and FUJIFILM. The company was founded in 1956 and is based in Bedford, Massachusetts.

CEO	Ms. Mary Anne Heino
WEBSITE	lantheus.com
SECTOR	Healthcare
INDUSTRY	Drug Manufacturers Specialty & Generic
EMPLOYEES	698

Lantheus Holdings Inc Frequently Asked Questions

What is the ticker symbol for Lantheus Holdings Inc? What does LNTH stand for in stocks?

LNTH is the stock ticker symbol of Lantheus Holdings Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Lantheus Holdings Inc (LNTH)?

As of Wed Dec 03 2025, market cap of Lantheus Holdings Inc is 3.96 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LNTH stock?

You can check LNTH's fair value in chart for subscribers.

Is Lantheus Holdings Inc a good stock to buy?

The fair value guage provides a quick view whether LNTH is over valued or under valued. Whether Lantheus Holdings Inc is cheap or expensive depends on the assumptions which impact Lantheus Holdings Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LNTH.

What is Lantheus Holdings Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, LNTH's PE ratio (Price to Earnings) is 23.64 and Price to Sales (PS) ratio is 2.6. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LNTH PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Lantheus Holdings Inc's stock?

In the past 10 years, Lantheus Holdings Inc has provided 0.315 (multiply by 100 for percentage) rate of return.